摘要:
Compounds (I) are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2 -mediated diseases, CCR9 -mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要:
Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要:
A compound of the formula (I) for treating a CCR2-mediated condition or disease or a CCR9-mediated condition or disease, where the disease or condition is selected from the group consisting of atherosclerosis, restenosis, multiple sclerosis, inflammatory bowel disease, renal fibrosis, rheumatoid arthritis, obesity, diabetes, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, idiopathic pneumonia syndrome, pulmonary fibrosis, transplantation rejection, graft- versus- host disease, cancer, and neuropathic pain wherein Ar is selected from the group consisting of substituted or unsubsituted Cβ-io aryl and substituted or unsubstituted 5- to 10- membered heteroaryl; Y1 to Y4 are selected from the group consisting of -CR3a- to -CR3d-, -N-, and -N+(O)-, wherein at least one of Y1, Y2, Y3, or Y4 is -N-.
摘要:
Compounds (I) are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2 -mediated diseases, CCR9 -mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
摘要:
A compound of the formula (I) for treating a CCR2-mediated condition or disease or a CCR9-mediated condition or disease, where the disease or condition is selected from the group consisting of atherosclerosis, restenosis, multiple sclerosis, inflammatory bowel disease, renal fibrosis, rheumatoid arthritis, obesity, diabetes, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, idiopathic pneumonia syndrome, pulmonary fibrosis, transplantation rejection, graft- versus- host disease, cancer, and neuropathic pain wherein Ar is selected from the group consisting of substituted or unsubsituted Cβ-io aryl and substituted or unsubstituted 5- to 10- membered heteroaryl; Y1 to Y4 are selected from the group consisting of -CR3a- to -CR3d-, -N-, and -N+(O)-, wherein at least one of Y1, Y2, Y3, or Y4 is -N-.
摘要:
Compounds of formula (I) (in which the variables L, X, Y and Z are as defined in the claims) are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulphonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
摘要:
A novel crystalline form of the sodium salt of 4- tert -butyl- N -[4-chloro-2-(1- oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide and pharmaceutical compositions containing the same are disclosed. Processes for the preparation thereof and methods for use thereof are also disclosed.